MASH / NASH (Fatty Liver Disease) Clinical Trials near Austin, TX
16 studies for MASH / NASH (Fatty Liver Disease) are recruiting at 50 sites within 50 miles of Austin, Texas, according to ClinicalTrials.gov data processed .
Distances are city-level approximations. See all MASH / NASH (Fatty Liver Disease) trials in the US or all trials near Austin.
Recruiting now
MASH / NASH (Fatty Liver Disease) studies enrolling near Austin
- A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169
- Phase 3
- Ages 18 to 80 years
- Sex: All
Nearest sites: 89bio Clinical Study Site (Austin, TX); 89bio Clinical Study Site (Austin, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 5 sites within 50 mi
- A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374
- Phase 3
- Ages 18 to 75 years
- Sex: All
Nearest sites: 89bio Clinical Study Site (Austin, TX); 89bio Clinical Study Site (Austin, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 5 sites within 50 mi
- LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: American Research Corporation - Austin (Austin, TX); IMA Clinical Research Austin (Austin, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 5 sites within 50 mi
- LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: American Research Corporation - Austin (Austin, TX); IMA Clinical Research Austin (Austin, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 5 sites within 50 mi
- A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
NCT06920043
- Phase 2
- Ages 18 to 75 years
- Sex: All
Nearest sites: GSK Investigational Site (Austin, TX); GSK Investigational Site (Austin, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 4 sites within 50 mi
- A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
NCT05519475
- Phase 2
- Ages 18 to 75 years
- Sex: All
Nearest sites: American Research Corporation (Austin, TX); Pinnacle Clinical Research - Austin (Austin, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 3 sites within 50 mi
- A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716
- Phase 3
- Ages 18 to 80 years
- Sex: All
Nearest sites: Akero Clinical Study Site (Austin, TX); Akero Clinical Study Site (Austin, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 3 sites within 50 mi
- A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314
- Phase 3
- Ages 18 to 80 years
- Sex: All
Nearest sites: Akero Clinical Study Site (Austin, TX); Akero Clinical Study Site (Austin, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 3 sites within 50 mi
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: American Research Corporation (Austin, TX); IMA Clinical Research Austin (Austin, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 3 sites within 50 mi
- A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
NCT07221227
- Phase 3
- Ages 18 to 75 years
- Sex: All
Nearest sites: GSK Investigational Site (Austin, TX); GSK Investigational Site (Austin, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 3 sites within 50 mi
- A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07491458
- Phase 2
- Ages 30 years and older
- Sex: All
Nearest sites: IMA Clinical Research (Austin) (Austin, TX); Pinnacle Clinical Research - Austin (Austin, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 3 sites within 50 mi
- A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
NCT07221188
- Phase 3
- Ages 18 to 75 years
- Sex: All
Nearest sites: GSK Investigational Site (Austin, TX); GSK Investigational Site (Austin, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07288138
- Phase 2
- Ages 18 to 75 years
- Sex: All
Nearest sites: Pinnacle Clinical Research (Austin, TX); Pinnacle Clinical Research - Georgetown (Georgetown, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
NCT07527910
- Phase 2
- Ages 18 to 75 years
- Sex: All
Nearest sites: American Research Corporation (Austin, TX); Advanced Medical Trials (Georgetown, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07701993
- Phase 3
- Ages 18 to 75 years
- Sex: All
Nearest site: GSK Investigational Site (Austin, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 1 site within 50 mi
- A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07704892
- Phase 3
- Ages 18 to 75 years
- Sex: All
Nearest site: GSK Investigational Site (Austin, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 1 site within 50 mi
FAQ
Common questions
What is a clinical trial?
Is there compensation for joining a MASH / NASH (Fatty Liver Disease) clinical trial?
How do I check if I'm eligible?
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.